ITCI
- Intra-Cellular Therapies, Inc.
()
Overview
Company Summary
Intra-Cellular Therapies, Inc. (ITCI) is a biopharmaceutical company that primarily focuses on the discovery and development of innovative treatments for individuals affected by neuropsychiatric disorders. Their goal is to improve the lives of patients with debilitating conditions like schizophrenia, bipolar disorder, and major depressive disorder.
ITCI specializes in developing small-molecule drugs that target the underlying biology and mechanisms of these disorders. They have expertise in neuroscience, chemistry, and clinical development, allowing them to leverage cutting-edge research to develop potential therapeutics.
The company's flagship product is lumateperone (brand name Caplyta), which is an oral, selective serotonin receptor modulator that acts on multiple receptors in the brain to regulate neurotransmitter activity. Caplyta was approved by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of schizophrenia in adults.
In addition to Caplyta, Intra-Cellular Therapies has an extensive pipeline of drug candidates targeting various psychiatric and neurological conditions. They are continually conducting clinical trials to evaluate the safety and efficacy of these potential treatments.
ITCI's vision is to become a leader in discovering and developing molecular therapeutics for neuropsychiatric disorders, addressing the unmet medical needs of patients worldwide. By combining scientific expertise with a patient-centered approach, they strive to bring hope and improved treatment options to those suffering from these challenging conditions.